重组人血小板生成素治疗急性白血病化疗后血小板减少的临床观察  被引量:6

The clinical efficacy of recombinant human thrombopoietin for treating thrombocytopenia after chemotherapy in acute leukemia patients

在线阅读下载全文

作  者:黎民君[1] 郭丽堃[1] 钟缨红[1] 冯思琼[1] 

机构地区:[1]广东省梅州市人民医院血液内科,广东梅州514000

出  处:《中国当代医药》2014年第1期114-115,121,共3页China Modern Medicine

摘  要:目的探究重组人血小板生成素(rhTPO)在急性白血病化疗后血小板减少治疗中的临床效果。方法选取本院2009年1月~2013年1月收治的50例急性白血病化疗后血小板减少患者为研究对象,将患者根据治疗方式的不同分为实验组与对照组,其中实验组在化疗结束后24h皮下注射rhTPO15000U,而对照组患者未给予rhTPO治疗。监测两组患者4、8、12、24d后的血小板动态变化情况及化疗后两组患者血小板恢复情况。结果化疗4d后,两组患者血小板水平差异无统计学意义(P〉0.05);而化疗8、12d后,实验组患者血小板水平显著高于对照组(P〈0.01);化疗24d后,两组患者血小板水平均恢复,组间差异无统计学意义(P〉0.05)。化疗后实验组患者血小板≤30×10^9/L的持续时间与血小板≥50×10^9/L所需时间均显著低于对照组,差异具有统计学意义(P〈0.05)。结论rhTPO可减少急性白血病化疗后血小板的降低的程度以及持续时间,同时其毒副作用也比较小,值得临床推广应用。Objective To explore the clinical efficacy of recombinant human thrombopoietin (rhTPO) for treating throm- bocytopenia after chemotherapy in acute leukemia patients. Methods 50 thrombocytopenia patients with acute leukemia after chemotherapy who were treated in our hospital from January 2009 to January 2013 were selected as the research objects, all patients were divided into the experimental group and the control group according to the drug treatment, pa- tients in the experimental group were given rhTPO 15 000 U by subcutaneous injection at 24 hour after chemotherapy, while patients in the control group were not given this type of treatment. The platelet dynamic change in 4,8,12,24 day were monitored. The platelet recovery of two groups of patients after chemotherapy were monitored. Results There was no statistically significant difference between patients in platelet level of two groups after 4 days chemotherapy (P〉0.05); the platelet count in the experimental group were higher than that of the control group after 8 clays and 12 days chemotherapy (P〈0.01); the platelet level of two groups patients were recovered after 24 days chemotherapy, there was no significant difference between the two groups (P〉0.05). BPC ≤ 30×10^9/L duration time and ~ 50× 10^9/L required time in the experimental group were significantly lower than that of the control group (P〈0.05). Conclusion rhTPO can reduce the platelet level of thrombocytopenia patients with acute leukemia after chemotherapy, reduce the duration time and its relative side effects, it is worthy of clinical application.

关 键 词:重组人血小板生成素 白血病 化疗 血小板减少 

分 类 号:R733.71[医药卫生—肿瘤]

 

参考文献:

正在载入数据...

 

二级参考文献:

正在载入数据...

 

耦合文献:

正在载入数据...

 

引证文献:

正在载入数据...

 

二级引证文献:

正在载入数据...

 

同被引文献:

正在载入数据...

 

相关期刊文献:

正在载入数据...

相关的主题
相关的作者对象
相关的机构对象